Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT06959615 für Fortgeschrittener solider Tumor ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration Phase 1, Phase 2 334 Dosis-Eskalation Offene Studie
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06959615 untersucht Behandlung im Zusammenhang mit Fortgeschrittener solider Tumor. Diese interventionsstudie der Phase 1 Phase 2 hat den Status offene rekrutierung und startete am 22. November 2024. Es ist geplant, 334 Teilnehmer aufzunehmen. Durchgeführt von Jacobio Pharmaceuticals Co., Ltd. wird der Abschluss für 31. August 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 20. Januar 2026 aktualisiert.
Kurzbeschreibung
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Ausführliche Beschreibung
Study JAB-23E73-1001 is a global multicenter, open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of JAB-23E73 as a single agent in adult patients with advanced solid tumors with KRAS alteration. This study consists of a Phase 1a dose-escalation, followed by Phase 1b dose-expansion (dose optimization) and Phase 2a indication expansi...Mehr anzeigen
Offizieller Titel
A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Erkrankungen
Fortgeschrittener solider TumorWeitere Studien-IDs
- JAB-23E73-1001
NCT-Nummer
Studienbeginn (tatsächlich)
2024-11-22
Zuletzt aktualisiert
2026-01-20
Studienende (vorauss.)
2027-08-31
Geplante Rekrutierung
334
Studientyp
Interventionsstudie
PHASE
Phase 1
Phase 2
Phase 2
Status
Offene Rekrutierung
Stichwörter
KRAS
KRAS mutation
KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12D
Pan-KRAS
NSCLC
Pancreas cancer
Colorectal cancer
KRAS-mutant tumor
Targeted Therapy
JAB-23E73
KRAS mutation
KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12D
Pan-KRAS
NSCLC
Pancreas cancer
Colorectal cancer
KRAS-mutant tumor
Targeted Therapy
JAB-23E73
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht randomisiert
Interventionsmodell
Sequentiell
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellPhase 1 Dose Exploration Monotherapy, dose escalation | JAB-23E73 Administered orally |
ExperimentellPhase 2a Dose Expansion Monotherapy, dose expansion | JAB-23E73 Administered orally |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Phase 1: Number of participants with dose limiting toxicities (DLT) | Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. DLTs will be defined as the occurrence of any of the toxicities as described in the protocol. | Up to 21 days |
Phase 2a: Objective response rate (ORR) | ORR is defined as the proportion of patients with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1. | Up to approximately 2 years |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Phase 1/2a: Adverse events | Incidence and severity of treatment-emergent Adverse Events (TEAEs), treatment-related Adverse Events (TRAEs) and serious Adverse Events (SAEs) | Up to approximately 2 years |
Phase 1/2a: Pharmacokinetic (PK): Maximum concentration (Cmax) of JAB-23E73 | PK: Cmax of JAB-23E73 | Up to approximately 2 years |
Phase 1/2a: PK: Time to Maximum Concentration (Tmax) of JAB-23E73 | PK: Tmax of JAB-23E73 | Up to approximately 2 years |
Phase 1/2a: PK: Area Under the Concentration Versus Time Curve (AUC) of JAB-23E73 | PK: AUC of JAB-23E73 | Up to approximately 2 years |
Phase 1: ORR | ORR is defined as the proportion of patients with a BOR of confirmed CR or confirmed PR per RECIST v1.1. | Up to approximately 2 years |
Phase 1/2a: Time to Response (TTR) | TTR is defined as the time from the date of first dose of study drug to first documentation of response as assessed by the investigator per RECIST v1.1 | Up to approximately 2 years |
Phase 1/2a: Progression Free Survival (PFS) | PFS is defined as the time from the date of the first dose of study drug to the date of the first documentation of progressive disease assessed by the investigator per RECIST v1.1 or death, whichever occurs first. | Up to approximately 2 years |
Phase 1/2a: Disease Control Rate (DCR) | DCR is defined as the proportion of patients with CR, PR, or stable disease (SD) as assessed by the investigator per RECIST v1.1 | Up to approximately 2 years |
Phase 1/2a: Duration of Response (DoR) | DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first as assessed by the investigator. | Up to approximately 2 years |
Phase 2a: Overall Survival (OS) | OS is defined as the time from the date of first dose of study drug until the date of death from any cause. | Up to approximately 2 years |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Zugelassene Geschlechter
Alle
- Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification).
- Able to provide an archived tumor tissue sample or fresh biopsy sample.
- Life expectancy ≥3 months at the start of treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ≥1 measurable lesion per RECIST v1.1.
- Adequate organ function.
- Unable to swallow oral medications or with gastrointestinal dysfunction or gastrointestinal disease that significantly alters the absorption of medication.
- Previous treatment with rat sarcoma (RAS) targeting agents.
- Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.
- Impaired cardiovascular function or clinically significant cardiac disease.
- Mean QT interval corrected using Fridericia's formula (QTcF) >470 msec.
- Females who are pregnant or breastfeeding.
Jacobio Pharmaceuticals Co., Ltd.Zentrale Studienkontakte
Kontakt: Jacobio Pharmaceuticals, 86 10 56315466, [email protected]
32 Studienstandorte in 1 Ländern
Anhui
Anhui Provincial Cancer Hospital, Hefei, Anhui, 230001, China
Noch nicht rekrutierend
Beijing Municipality
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, 100021, China
Offene Rekrutierung
Beijing Cancer Hospital, Beijing, Beijing Municipality, 100032, China
Offene Rekrutierung
Beijing Chest Hospital, Beijing, Beijing Municipality, 100032, China
Offene Rekrutierung
Peking Union Medical College Hospital, Beijing, Beijing Municipality, 100032, China
Offene Rekrutierung
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality, 100050, China
Noch nicht rekrutierend
Fujian
Fujian cancer Hospital, Fuzhou, Fujian, 350014, China
Noch nicht rekrutierend
Guangdong
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China
Offene Rekrutierung
Guangxi
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530012, China
Offene Rekrutierung
Hebei
National Cancer Center/Cancer Hospital- Langfang Campus, Chinese Academy of Medical Sciences and Peking Union Medical College, Langfang, Hebei, 065000, China
Offene Rekrutierung
Heilongjiang
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, 150081, China
Offene Rekrutierung
Henan
Henan Cancer Hospital, Zhengzhou, Henan, 450003, China
Offene Rekrutierung
The First Affiliated hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China
Offene Rekrutierung
Hubei
Tongji Hospital, Wuhan, Hubei, 430030, China
Noch nicht rekrutierend
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
Offene Rekrutierung
Hunan
Hunan Cancer Hospital, Changsha, Hunan, 200032, China
Noch nicht rekrutierend
Jiangsu
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210008, China
Offene Rekrutierung
Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210009, China
Noch nicht rekrutierend
Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China
Offene Rekrutierung
The First Affiliate of Soochow University, Suzhou, Jiangsu, 215006, China
Noch nicht rekrutierend
Jiangxi
The First Affiliated hospital of Nanchang University, Nanchang, Jiangxi, 330006, China
Offene Rekrutierung
Liaoning
The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China
Offene Rekrutierung
Shanghai Municipality
Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, Shanghai Municipality, 200025, China
Noch nicht rekrutierend
Fudan University Zhongshan Hospital, Shanghai, Shanghai Municipality, 200032, China
Noch nicht rekrutierend
Huashan Hospital Fudan University, Shanghai, Shanghai Municipality, 200040, China
Noch nicht rekrutierend
Shanxi
ShanXi Cancer Hospital, Taiyuan, Shanxi, 650118, China
Offene Rekrutierung
The First Affiliated hospital of Xi'an Jiaotong University, Xi’an, Shanxi, 710061, China
Noch nicht rekrutierend
Sichuan
West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
Noch nicht rekrutierend
Tianjin Municipality
Tianjin Medical University Cancer Institute&Hospital, Tianjin, Tianjin Municipality, 300211, China
Noch nicht rekrutierend
Zhejiang
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310005, China
Offene Rekrutierung
The Second Affiliate Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China
Noch nicht rekrutierend
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China
Noch nicht rekrutierend